Selected article for: "clinical benefit and inflammatory response"
Author: Moreno-Olmedo, Elena; Suárez-Gironzini, Vladimir; Pérez, Manuel; Filigheddu, Teresa; Mínguez, Cristina; Sanjuan-Sanjuan, Alba; González, José A.; Rivas, Daniel; Gorospe, Luis; Larrea, Luis; López, Escarlata
Title: COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases
  • Cord-id: 2tg3v2tc
  • Document date: 2021_1_27
    • ID: 2tg3v2tc
    Snippet: INTRODUCTION: Since the outbreak of coronavirus disease 2019 (COVID-19) pandemic, healthcare systems have focused their efforts into finding a treatment to avoid the fatal outcomes of severe acute respiratory syndrome due to coronavirus‑2 (SARS-CoV-2). Benefits and risks of systemic treatments remain unclear, with multiple clinical trials still ongoing. Radiotherapy could play a role in reducing the inflammatory response in the lungs and relieve life-threatening symptoms. METHODS: We designed
    Document: INTRODUCTION: Since the outbreak of coronavirus disease 2019 (COVID-19) pandemic, healthcare systems have focused their efforts into finding a treatment to avoid the fatal outcomes of severe acute respiratory syndrome due to coronavirus‑2 (SARS-CoV-2). Benefits and risks of systemic treatments remain unclear, with multiple clinical trials still ongoing. Radiotherapy could play a role in reducing the inflammatory response in the lungs and relieve life-threatening symptoms. METHODS: We designed a prospective study of Ultra-Low Doses of Therapy with Radiation Applied to COVID-19 (ULTRA-COVID) for patients who suffer pneumonia, are not candidates for invasive mechanical ventilation and show no improvement with medical therapy. RESULTS: We present the preliminary results of two patients diagnosed with COVID-19 pneumonia treated with ULTRA-COVID. After one radiotherapy session, significant clinical response and a good radiological response was observed in both cases, resulting in both patients being discharged from hospital in less than 2 weeks after radiation treatment. CONCLUSION: Preliminary clinical and radiological results suggest a potential benefit of treating COVID-19 pneumonia with ULTRA-COVID. ClinicalTrials.gov Identifier: NCT04394182

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and long term sequelae: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and administer single dose: 1
    • acute respiratory syndrome and local ethic committee: 1
    • acute respiratory syndrome and long follow period: 1, 2, 3
    • acute respiratory syndrome and long term sequelae: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir kaletra ritonavir: 1, 2, 3, 4
    • acute significant and long term sequelae: 1